Physician profile
Alejandro Carvallo
NPI 1053416412
$2,284.27
in general payments reported to CMS, 2019-2025
23 companies · $20.62 in 2025
The $20.62 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $291 · 2021: $677 · 2022: $67.78 · 2025: $20.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $562.96 | 2019-2022 | |
| Horizon Therapeutics Plc | $256.42 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $196.34 | 2019-2021 | |
| Daiichi Sankyo INC. | $190.33 | 2019-2021 | |
| Akebia Therapeutics INC | $177.42 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $158.51 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $150.18 | 2019 | |
| Vifor Pharma, INC. | $108.93 | 2019-2021 | |
| Amgen INC. | $75.88 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.96 | 2021 | |
| Baxter Healthcare | $65.92 | 2019-2021 | |
| Glaxosmithkline, LLC. | $41.45 | 2021 | |
| Mallinckrodt Hospital Products INC. | $28.45 | 2021 | |
| Abbvie INC. | $27.79 | 2022 | |
| Fresenius USA Marketing, INC. | $26.67 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $24.32 | 2021 | |
| Bard Peripheral Vascular, INC. | $20.73 | 2021 | |
| Boston Scientific Corporation | $20.62 | 2025 | Varithena Administration Pack |
| Takeda Pharmaceuticals U.S.A., INC. | $19.72 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.29 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.37 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.74 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Carvallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.